Securities Registration (section 12(b)) (8-a12b)
February 10 2016 - 09:55AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
PROTEOSTASIS
THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
20-8436652 |
(State of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
|
|
200 Technology Square, 4th Floor
Cambridge, MA |
|
02139 |
(Address of principal executive offices) |
|
(Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class
to be so registered |
|
Name of each exchange on which
each class is to be registered |
Common Stock, par value $0.001 per share |
|
The NASDAQ Stock Market LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General
Instruction A.(c), please check the following box. x
If this form relates to the registration
of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box. ¨
Securities Act registration statement file number to which this form relates:
333-208735
Securities
to be registered pursuant to Section 12(g) of the Act:
None
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 1. |
Description of Registrants Securities to be Registered. |
For a description of the
Registrants common stock, par value $0.001 per share, to be registered hereunder, reference is made to the information set forth under the heading Description of Capital Stock Common Stock in the Registrants prospectus
that constitutes a part of the Registrants Registration Statement on Form S-1, as amended (File No. 333-208735) (the Registration Statement), filed with the Securities and Exchange Commission (the Commission) under
the Securities Act of 1933, as amended (the Securities Act), which information is hereby incorporated by reference. Any form of the prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under
the Securities Act that constitutes part of the Registration Statement shall be deemed to be incorporated herein by reference.
Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits
are required to be filed, because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of
1934, as amended.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration
statement to be signed on its behalf by the undersigned, thereto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PROTEOSTASIS THERAPEUTICS, INC. |
|
|
|
|
Date: February 10, 2016 |
|
|
|
By: |
|
/s/ Meenu Chhabra |
|
|
|
|
|
|
Meenu Chhabra |
|
|
|
|
|
|
President and Chief Executive Officer |
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Mar 2023 to Mar 2024